Dr. Nathan on 5-Year Survival Outcomes of COMBI-d and COMBI-v Trials in BRAF V600-Mutant Melanoma

Paul D. Nathan, MBBS, PhD, FRCP
Published: Wednesday, Jul 31, 2019



Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the 5-year analysis of the COMBI-d and COMBI-v trials, which look at the long-term effects of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

At the 5-year follow-up, the progression-free survival rate was 19% and the overall survival rate was 34%. There is a cohort of patients who do well on the combination long term, according to Nathan. Now, physicians must figure out how to identify who is going to respond well to the combination at the baseline. Physicians have corroborated some earlier data based on a multivariate analysis and a regression tree analysis, looking at baseline characteristics to identify who is likely to do well, according to Nathan.

Physicians found some markers that are associated with durability of response, including whether someone has a normal lactate dehydrogenase, fewer than 3 organ sites involved, and a good performance status. The most powerful marker of durability of response is whether somebody has a complete response (CR) to treatment. However, that is not a baseline marker; rather, it is a marker that is generated while a patient is on treatment. In the trial, 19% of patients had a CR to treatment. In the 5-year outcome for the patients who had a CR, 49% were progression free and 71% were alive at 5 years.
SELECTED
LANGUAGE


Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the 5-year analysis of the COMBI-d and COMBI-v trials, which look at the long-term effects of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

At the 5-year follow-up, the progression-free survival rate was 19% and the overall survival rate was 34%. There is a cohort of patients who do well on the combination long term, according to Nathan. Now, physicians must figure out how to identify who is going to respond well to the combination at the baseline. Physicians have corroborated some earlier data based on a multivariate analysis and a regression tree analysis, looking at baseline characteristics to identify who is likely to do well, according to Nathan.

Physicians found some markers that are associated with durability of response, including whether someone has a normal lactate dehydrogenase, fewer than 3 organ sites involved, and a good performance status. The most powerful marker of durability of response is whether somebody has a complete response (CR) to treatment. However, that is not a baseline marker; rather, it is a marker that is generated while a patient is on treatment. In the trial, 19% of patients had a CR to treatment. In the 5-year outcome for the patients who had a CR, 49% were progression free and 71% were alive at 5 years.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x